Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Structure’s pill is part of the same class of drugs as Novo Nordisk’s blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy.

Previous post Citigroup CEO Jane Fraser sees ‘cracks’ emerging among some consumers as savings dry up
Next post : McCarthy maintains tough tone as government shutdown on Sunday looks unavoidable